InspireMD (NYSE:NSPR) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Friday. The firm set a “sell” rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and set a $4.50 price target on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Down 0.4 %

Shares of NSPR opened at $2.45 on Friday. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.77. The firm has a market capitalization of $61.08 million, a price-to-earnings ratio of -3.31 and a beta of 0.91. The stock’s 50-day moving average price is $2.69 and its 200 day moving average price is $2.56.

InspireMD (NYSE:NSPR) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The firm had revenue of $1.74 million for the quarter, compared to the consensus estimate of $1.74 million. During the same quarter in the prior year, the firm earned ($0.24) earnings per share. Equities research analysts expect that InspireMD will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC acquired a new position in shares of InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.